News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antares Pharma, Inc. (ANTR) Receives Milestone Payment and Additional Patent Related to Elestrin(R)


1/6/2009 8:44:32 AM

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) announced that the company received a milestone payment of $450,000 from BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) related to an agreement with AZUR Pharma for the marketing of Elestrin (estradiol gel) to treat moderate to severe hot flashes in menopausal women in the United States. BioSante received $3.325 million on signing with AZUR, of which approximately $1.5 million was purchased inventory. Antares is entitled to 25 percent of any upfront and milestone payments as well as a percentage of product royalties. AZUR has agreed to market Elestrin using its women’s health and urology sales force of approximately 50 sales people that target estrogen prescribing physicians in the U.S. comprised mostly of gynecologists.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES